Standout Papers

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-ce... 2013 2026 2017 2021 688
  1. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study (2016)
    Matthew D. Hellmann, Naiyer A. Rizvi et al. The Lancet Oncology
  2. Programmed death ligand-1 expression in non-small cell lung cancer (2013)
    Vamsidhar Velcheti, Kurt A. Schalper et al. Laboratory Investigation
  3. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study (2018)
    Scott Gettinger, Leora Horn et al. Journal of Clinical Oncology
  4. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial (2017)
    Dong‐Wan Kim, Marcello Tiseo et al. Journal of Clinical Oncology
  5. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab (2019)
    Suzanne L. Topalian, F. Stephen Hodi et al. JAMA Oncology
  6. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors (2018)
    Angeliki M. Stamatouli, Zoe Quandt et al. Diabetes
  7. Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer (2016)
    Scott Gettinger, Naiyer A. Rizvi et al. Journal of Clinical Oncology
  8. Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer (2016)
    Naiyer A. Rizvi, Matthew D. Hellmann et al. Journal of Clinical Oncology
  9. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA (2018)
    Sarah B. Goldberg, Azeet Narayan et al. Clinical Cancer Research
  10. Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors (2024)
    Adam J. Schoenfeld, Scott Gettinger et al. Cancer Discovery

Immediate Impact

17 by Nobel laureates 7 from Science/Nature 143 standout
Sub-graph 1 of 15

Citing Papers

Immune checkpoint therapy—current perspectives and future directions
2023 StandoutNobel
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
12 intermediate papers

Works of Scott Gettinger being referenced

Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling
2020
NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.
2018
and 13 more

Author Peers

Author Last Decade Papers Cites
Scott Gettinger 9980 6665 1688 2783 255 12.8k
Katsuyuki Hotta 10920 8489 1691 2044 286 13.7k
Naiyer A. Rizvi 10797 7606 2182 3473 274 14.6k
Maya Gottfried 10411 7572 1690 1889 155 12.9k
Ji‐Youn Han 9442 8002 2096 2992 255 12.8k
Laura Q.M. Chow 8861 4544 1594 2795 156 12.1k
Rina Hui 11054 7176 1871 1810 169 13.8k
Geoffrey R. Weiss 7763 4353 1438 3989 191 12.3k
Mark M. Awad 7516 5631 1658 2312 268 10.4k
Joo-Hang Kim 8190 6612 1577 3050 145 11.4k
Delvys Rodríguez‐Abreu 14669 9848 1958 1927 183 17.4k

All Works

Loading papers...

Rankless by CCL
2026